Miguel Muñoz

16PUBLICATIONS
24CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursPsychopharmacology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 26, 2026
Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer.

|Nov 27, 2025
The Involvement of the Peptidergic Systems in Breast Cancer Development.

Manuel L Sánchez, Prema Robinson, Zal Italia

|Oct 16, 2025
A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer.

Miguel Muñoz, Rafael Coveñas, Younus Zuberi

|Feb 13, 2025
Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Miguel Muñoz, Marisa Rosso

|Nov 14, 2023
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.

Rafael Coveñas, Francisco D Rodríguez, Prema Robinson

|Oct 14, 2023
Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.

Inmaculada Isorna, Miguel Ángel González-Moles, Miguel Muñoz

Pageof 3

Frequent Collaborators

7 joint publications

Rafael Coveñas

4 joint publications

Marisa Rosso

2 joint publications

Tan Hoang

2 joint publications

Miguel Ángel González-Moles